Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28707277 | 1.00 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1ABCB1USP30 | |
| SCHEMBL23012137 | 0.85 | GHSR (0.42) | SMARCA2SMARCA4PBRM1ABCB1USP30 | |
| SCHEMBL23033355 | 0.84 | KMT2A (0.48) | MEN1KMT2AATMGPR119GLS | |
| SCHEMBL23012077 | 0.83 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1ABCB1USP30 | |
| SCHEMBL23034197 | 0.81 | USP30 (0.40) | USP30MEN1KMT2AATMGPR119 | |
| SCHEMBL29479763 | 0.80 | MEN1 (0.39) | USP30MEN1KMT2AATMGPR119 | |
| SCHEMBL29479717 | 0.80 | EGFR (0.38) | USP30MEN1KMT2AATMGPR119 | |
| SCHEMBL31165945 | 0.80 | ATM (0.41) | USP30MEN1KMT2AATMGPR119 | |
| SCHEMBL10073179 | 0.78 | CCR5 (0.48) | SMARCA2SMARCA4PBRM1ABCB1USP30 | |
| SCHEMBL29479761 | 0.78 | CYP2D6 (0.48) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269725-B | Anti-influenza virus compound, preparation method and application thereof | 西藏海思科制药有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20230079045-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-03-16 | — | — | US | disclosed |
| CN-114269725-A | Anti-influenza virus compound and preparation method and application thereof | 四川海思科制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079045-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | IDE, ACE, SI | SMARCA2 1270/4885SMARCA4 1135/4885PBRM1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.